Wall Street analyst estimates for Avantor, Inc. (AVTR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises.
Consensus price target
$14.55 (-9 % vs price $16.05)
between $7.00 and $18.00 · 5 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $6.6B | $6.6B – $6.6B | $0.81 | 9 |
| 2027E | $6.7B | $6.7B – $6.8B | $0.88 | 8 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 16 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 26 |
| Avg rating (−2 sell to +2 buy) | 0.23 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-10 | $0.23 | ||
| 2026-10-28 | $0.22 | $0.21 | +5.3% |
| 2026-07-29 | $0.21 | $0.19 | +9.7% |
| 2026-04-29 | $0.17 | $0.16 | +8.3% |
| 2026-02-11 | $0.22 | $0.21 | +4.8% |
| 2025-10-29 | $0.22 | $0.22 | -2.1% |
| 2025-08-01 | $0.24 | $0.25 | -4.0% |
| 2025-04-25 | $0.23 | $0.23 | -0.6% |
Valuation Ratios
| P/E Ratio | 32.05 |
| Price / Book | 1.86 |
| EV / EBITDA | 15.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $691.3M | $1.25B | $5.86B | $6.04B | $6.39B | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B |
| Cost of Revenue | $371.6M | $814.6M | $4.04B | $4.12B | $4.31B | $4.88B | $4.91B | $4.60B | $4.50B | $4.41B |
| Gross Profit | $319.7M | $432.8M | $1.82B | $1.92B | $2.08B | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B |
| Research & Development | $19.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $309.8M | $643.2M | $1.41B | $1.37B | $1.37B | $1.53B | $1.47B | $1.51B | $1.64B | $1.60B |
| Operating Expenses | $309.8M | $643.2M | $1.41B | $1.37B | $1.37B | $1.53B | $1.47B | $1.67B | $1.19B | $2.39B |
| Operating Income | $9.9M | -$210.4M | $413.5M | $551.8M | $706.8M | $972.2M | $1.13B | $696.4M | $1.08B | -$246.2M |
| EBITDA | $70.0M | -$160.1M | $814.6M | $879.5M | $765.3M | $1.35B | $1.52B | $1.10B | $1.48B | $138.7M |
| Interest Expense | $80.3M | $200.9M | $523.8M | $440.0M | $307.6M | $217.4M | $265.8M | $284.8M | $218.8M | $169.8M |
| Pre-tax Income | -$70.6M | -$460.2M | -$113.8M | $40.6M | $62.3M | $753.0M | $851.1M | $410.5M | $853.9M | -$441.3M |
| Income Tax | $10.1M | -$314.9M | -$26.9M | $2.8M | -$54.3M | $180.4M | $164.6M | $89.4M | $142.4M | $88.9M |
| Net Income | -$42.4M | -$112.7M | -$86.9M | $37.8M | $116.6M | $572.6M | $686.5M | $321.1M | $711.5M | -$530.2M |
| EPS | $-0.09 | $-0.84 | $-0.72 | $-0.84 | $0.09 | $0.86 | $1.02 | $0.48 | $1.05 | $-0.78 |
| EPS (Diluted) | $-0.09 | $-0.84 | $-0.72 | $-0.84 | $0.09 | $0.85 | $1.01 | $0.47 | $1.04 | $-0.78 |
| Shares Outstanding (Diluted) | 491.3 M | 496.5 M | 496.5 M | 401.2 M | 583.4 M | 599.6 M | 679.4 M | 678.4 M | 681.9 M | 679.3 M |
Price
| Price | $16.05 (closing price, October 30, 2026) |
| Market Cap | $10.9B |
| Exchange | NYSE |
| Country | US |
Related companies: RGEN · DHR · WST · CRL · BIO · STVN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of AVTR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks